A new study by researchers at King's College London has split schizophrenia risk into two genetically distinct pathways. One is characterized by a shared genetic risk with bipolar disorder and ...

It’s a frustration for both doctors who treat patients with schizophrenia and for people living with it: the most effective antipsychotic drugs have side effects, so unpleasant patients would rather ...

Antibodies from llamas could be used to create a new generation of schizophrenia treatments that can effectively target the brain, rather than just reducing symptoms. This is the promise of a study ...

Flinders University researchers have discovered a rare genetic mutation that could explain why some people do not respond to ...

The U.S. Food and Drug Administration approved Cobenfy on September 26, 2024, making it the first schizophrenia drug with a ...

Researchers found that, compared with controls, intrinsic cellular age was slowed in schizophrenia cases in young adulthood, particularly in males, while phenotypic age was accelerated in later adults ...

Ketogenic diets do show promise for schizophrenia and bipolar disorder, but the research is preliminary and not backed by ...

The Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), making it the first major advancement in schizophrenia treatment in decades. Unlike existing medications that ...

Three distinct symptoms characterized schizophrenia: positive, negative, and cognitive. Positive symptoms (delusions and hallucinations) improve with typical or atypical antipsychotic medications.

The FDA on Thursday approved xanomeline and trospium chloride (Cobenfy) for schizophrenia in adults, the first new class of drug for the condition in more than 30 years. In contrast to antipsychotics ...

A compound found in marijuana can treat schizophrenia as effectively as antipsychotic medications, with far fewer side effects, according to a preliminary clinical trial. Researchers led by Markus ...